Tripos Releases Industry-Leading SYBYL Suite of Applications on HP Integrity Servers and Itanium-Based Workstations
ST. LOUIS – Sept. 10, 2003 – Tripos, Inc. (Nasdaq: TRPS), a leading provider of drug discovery informatics products and chemistry research, today announced the release of its industry-leading SYBYL® suite of applications on industry-standard HP Integrity servers and Intel Itanium-based workstations running the HP-UX operating system. Tripos’ computational chemistry software products are now available on three platforms: Linux, SGI and HP’s Itanium-based systems running HP-UX.
“The sophisticated tools that Tripos offers are positioned in multiple ways to take advantage of the ever-increasing computational power available,” said Dr. Trevor Heritage, senior vice president and general manager of discovery informatics at Tripos. “Our tools for QSAR, ADME and virtual screening, combined with the kind of computational power available in this new architecture, will allow our customers to perform virtual experiments and analysis unthinkable just several years ago.”
The leading role the Itanium series plays in scientific computing together with the Intel architecture should enable them to fulfill Moore’s Law of doubling computational power every 18 months. Tripos chose this strategic direction to continue its efforts to expedite the drug discovery process for the industry.
“HP today delivers industry-standard Itanium-based systems that use the world-class HP services and support organization to solve technical computing and application challenges,” said Winston Prather, vice president and general manager, High Performance Technical Computing, HP. “We work with a wide range of technical computing partners like Tripos, helping them to offer customers the flexibility of a high-performance technical platform for faster drug discovery.”
Tripos will be demonstrating its newly released SYBYL 6.9.1 modules, FlexX-Pharm™* and FUGUE™, on HP Itanium-based servers and workstations in Booth 303 at the American Chemical Society’s 226th National Meeting, being held at the Jacob K. Javits Convention Center in New York City Sept. 8-10, 2003.
About Tripos, Inc.
Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos partners with clients to accelerate and improve the creation of life-enhancing products. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com/.
# # #
* FlexX and FlexX-Pharm were developed by Dr. Sally Hindle and Prof. Dr. Matthias Rarey and their colleagues at the former GMD institute SCAI (now FhG) headed by Prof. Dr. Thomas Lengauer. BioSolveIT GmbH has acquired exclusive rights to distribute, further develop, and maintain FlexX and FlexX-Pharm.
This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as “expects,” “anticipates,” “projects,” “estimates,” “intends,” “plans,” “believes,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.
